CordenPharma Receives FDA Warning Letter
The company received a warning letter at its Latina facility in Sermoneta, Italy following a May 2015 inspection.
On May 27, 2016, CordenPharma notified customers about a warning letter the company received from FDA for its CordenPharma Latina facility in Sermoneta, Italy. The warning letter follows an inspection of the site by FDA in early May 2015, the company said in the statement.
The FDA warning letter cited several CGMP violations for finished pharmaceuticals and APIs. Some of these violations include visible “black grime and filth” in the aseptic area. Other violations included failure to sanitize equipment at appropriate intervals, failure to establish laboratory controls, unsound test procedures to test API quality, and a facility not designed to limit exposure to microbiological contamination.
The company said it will respond with a “comprehensive plan” to address FDA’s observations within 15 days. The company also noted the supply of any APIs and finished dosage forms will not be affected by the warning letter. The company said it will contact customers within the next 10 days to address the effects of the letter and highlight its response.
Source: CordenPharma, FDA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
